Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 5 for:    focused ultrasound parkinson's | Toronto, Canada
Previous Study | Return to List | Next Study

Blood-Brain-Barrier Disruption With Cerezyme in Patient's With Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04370665
Recruitment Status : Active, not recruiting
First Posted : May 1, 2020
Last Update Posted : January 12, 2021
Sponsor:
Information provided by (Responsible Party):
InSightec

Brief Summary:
This clinical trial focus on the delivery of Cerezyme® in Parkinson's Disease (PD) patients using MR-guided focused ultrasound (MRgFUS) induced opening of the blood-brain barrier (BBB).

Condition or disease Intervention/treatment Phase
Parkinson Disease Device: Exablate BBBD with Cerezyme Not Applicable

Detailed Description:
Leveraging the preclinical evidence and clinical experience with MRgFUS BBB opening in human subjects, the investigators propose a phase I open-label study to determine the safety and feasibility of three biweekly delivery of Cerezyme® (an analogue of the human enzyme beta-glucocerebrosidase) via MRgFUS induced BBB opening to unilateral putamen in PD. The putamen contains terminals of dopaminergic neurons from the substantia nigra, and is a critically affected brain region in PD. The primary objective is to determine the feasibility of repeated MRgFUS BBB opening for Cerezyme delivery in unilateral putamen. The secondary objective is to describe the safety and tolerability of the procedure. Another objective is to measure changes in PD relevant clinical scores and Cerezyme relevant biomarkers in the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: This is a prospective, single-center, single-arm, open-labelled study to enroll six (6) patients with Parkinson's disease for three biweekly deliveries of Cerezyme® to the unilateral putamen corresponding to the most affected side using Exablate and Definity®-induced BBB opening. This is a dose escalation study. Each subject will be followed for three months after the final procedure.
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: A Pilot Study for Brain Delivery of Cerezyme® in Patients With Parkinson's Disease Using MR-guided Focused Ultrasound Induced Opening of the Blood-brain Barrier
Actual Study Start Date : July 16, 2020
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : June 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Open label single arm
Using Exablate Model 4000 Type-2 to temporarily disrupt the blood brain barrier to deliver Cerezyme in patients with Parkinson's Disease.
Device: Exablate BBBD with Cerezyme

Blood Brain Barrier Disruption via Exablate to deliver Cerezyme.

Other Names:

Exablate Neuro





Primary Outcome Measures :
  1. Contrast enhancement on MR imaging [ Time Frame: Immediately after MRgFUS BBBD procedure ]
    MRgFUS BBB Opening will be determined qualitatively by contrast enhancement in the sonicated putamen on T1-weighted with gadolinium MRI, and quantitatively by the change in intensity relative to contralateral unsonicated putamen immediately after MRgFUS BBBD procedure.


Secondary Outcome Measures :
  1. Safety --Adverse events [ Time Frame: Through study completion, an average of 3 months ]
    Safety will be assessed by recording all adverse events and/or Serious Adverse Events that are BBBD related. Each Adverse Event will be documented for patterns of occurrence.


Other Outcome Measures:
  1. Exploratory effectiveness of Cerezyme delivery via MRgFUS BBB Opening [ Time Frame: 1 day after the final BBBD procedure ]
    Exploratory effectiveness of Cerezyme delivery via MRgFUS BBB Opening will be measured by changes in levels of Cerezyme (GCase) and GCase substrates levels (e.g. GL1 and glucosylsphingosine or lyso-GL1) in cerebralspinal fluid (CSF) samples.

  2. Exploratory effectiveness of Cerezyme treatment via MRgFUS BBB Opening [ Time Frame: 3 months after the final BBBD procedure. ]
    Exploratory effectiveness of Cerezyme treatment via MRgFUS BBB Opening will be measured by changes in cognitive impairment via Mini-Mental Status Exam (MMSE).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   35 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men or women between age 35 and 75 years, inclusive.
  2. Able and willing to give informed consent.
  3. Diagnosis of Parkinson's Disease.
  4. At least 2 years from initial diagnosis
  5. On stable regiment of PD medications for at least 90 days prior to the study
  6. Able to communicate during the Exablate MRgFUS procedure.
  7. Able to attend all study visits.

Exclusion Criteria:

  1. Previous neurosurgical procedure for PD
  2. Cerezyme hypersensitivity
  3. Patients who had recent intracranial hemorrhage or stroke
  4. Skull covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp. Patients who have clips or other metallic implanted objects in the skull or the brain.
  5. Patients who are on blood thinners within washout period prior to treatment (i.e., antiplatelet or vitamin K inhibitor anticoagulants within 7 days, non-vitamin K inhibitor anticoagulants within 72 hours, or heparin-derived compounds within 48 hours of treatment).
  6. Patients with a history of a bleeding disorder, blood clotting, coagulopathy or with a history of spontaneous tumor hemorrhage.
  7. Patients receiving bevacizumab (Avastin) therapy.
  8. Currently participating in another clinical therapeutic trial
  9. Documented myocardial infarction within six months of enrollment.
  10. Unstable angina on medication.
  11. Congestive heart failure.
  12. Unstable cardiac arrhythmia.
  13. Cardiac pacemaker.
  14. Severe hypertension (diastolic BP > 100 on medication).
  15. Documented cerebral infarction within the past 12 months or TIA in the past 1 month.
  16. Insulin-dependent diabetes mellitus that is not well-controlled or that in the Investigator's opinion precludes participation in the study.
  17. Known sensitivity to gadolinium
  18. Known sensitivity to DEFINITY ultrasound contrast agent or perflutren.
  19. Contraindications to MRI such as non-MRI-compatible implanted devices.
  20. Large subjects not fitting comfortably into the MRI scanner.
  21. Difficulty lying supine and still for up to 4 hours in the MRI unit or claustrophobia.
  22. Untreated, uncontrolled sleep apnea.
  23. Positive pregnancy test (for pre-menopausal women).
  24. Known life-threatening systemic disease.
  25. Severely impaired renal function and/or on dialysis.
  26. Right to left or bi-directional cardiac shunt.
  27. Subjects with evidence of cranial or systemic infection.
  28. Subjects with uncontrolled chronic pulmonary disorders.
  29. Subjects with a history of severe asthma, hay fever, or multiple allergies that is not well-controlled (e.g. with anaphylaxis).
  30. Subjects with a family or personal history of cardiac arrhythmia.
  31. Severe liver injury.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04370665


Locations
Layout table for location information
Canada, Ontario
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Sponsors and Collaborators
InSightec
Layout table for additonal information
Responsible Party: InSightec
ClinicalTrials.gov Identifier: NCT04370665    
Other Study ID Numbers: PD013
First Posted: May 1, 2020    Key Record Dates
Last Update Posted: January 12, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by InSightec:
Exablate
Focused Ultrasound
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases